Towards a new standard of care for patients with myeloma?

摘要

New agents such as immunomodulatory drugs and proteasome inhibitors have substantially changed the treatment paradigm of multiple myeloma, with the combinations melphalan-prednisone-thalidomide and melphalan-prednisone-bortezomib now regarded as new standards of care for elderly patients. Inyounger patients, the introduction of bortezomib into pre-transplant induction regimens and lenalidomide as consolidation-maintenance has showed promising results.